For patients when an OAB* medication fails

Six months between treatmentsand no daily OAB pills1

That’s the freedom of BOTOX®

View Access Data

When an anticholinergic is not working well enough or is intolerable, switch your patients to BOTOX® sooner. BOTOX® delivers significant reduction in daily leakage episodes with treatment as few as 2 times a year.1,‡,§

*Overactive bladder.

Anticholinergic.

Patients should be considered for reinjection when the effect of the previous injection has diminished but no sooner than 12 weeks from the prior injection.

§At week 12 in clinical trials.

For patients when an OAB* medication fails

Six months between treatmentsand no daily OAB pills1

That’s the freedom of BOTOX®

View Access Data

When an anticholinergic is not working well enough or is intolerable, switch your patients to BOTOX® sooner. BOTOX® delivers significant reduction in daily leakage episodes with treatment as few as 2 times a year.1,‡,§

*Overactive bladder.

Anticholinergic.

Patients should be considered for reinjection when the effect of the previous injection has diminished but no sooner than 12 weeks from the prior injection.

§At week 12 in clinical trials.

Assess your OAB patients’ readiness for BOTOX®

Many patients get stuck cycling through oral OAB medications that are not working or are intolerable2

Anticholinergic.

Anticholinergic.

≥ 80%

of patients would be willing to try a procedure3

(n = 127)

Use this 4-point scale with patients to categorize the severity of their primary axillary hyperhidrosis.

BOTOX® delivers significant, proven reductions in daily OAB leakage episodes

Mean reductions in daily leakage episodes at week 12 in patients who did not have success with or could not tolerate an anticholinergic (P < 0.001)

Mean reductions in daily leakage episodes at week 12 in patients who did not have success with or could not tolerate an anticholinergic (P < 0.001)

 

Study 1 and 2 design: Double-blind, placebo-controlled, randomized, multicenter, phase 3, 24-week clinical studies in OAB patients with symptoms of urge urinary incontinence (UUI), urgency and frequency who had an inadequate response to or intolerable side effects on anticholinergic therapy. Eligible patients had at least 3 UUI episodes and at least 24 micturition within 3 days. Patients were randomized to BOTOX® 100 Units (n = 557) or placebo (n = 548). Primary endpoint was the mean change from baseline daily UI episodes at week 12. ANACOVA model with last-observation-carried-forward (LOCF) imputation was used. Study 1 mean baseline UI frequency: BOTOX® 100 Units = 5.5/day, placebo = 5.7/day1

BOTOX® safety profile for OAB is well characterized

Most common adverse events were established in pivotal studies1

OAB is treated at its source

BOTOX® is injected directly into the detrusor during an in-office procedure1

Next Page